Korean J Pain.  2013 Oct;26(4):336-346. 10.3344/kjp.2013.26.4.336.

Role of Catheter's Position for Final Results in Intrathecal Drug Delivery. Analysis Based on CSF Dynamics and Specific Drugs Profiles

• Jose DA
• Luciano P
• Vicente V
• Juan Marcos AS
• Gustavo FC

• KMID: 2074041
• DOI: http://doi.org/10.3344/kjp.2013.26.4.336

Abstract

Intrathecal drug delivery is an effective and safe option for the treatment of chronic pathology refractory to conventional pain therapies. Typical intrathecal administered drugs are opioids, baclofen, local anesthetics and adjuvant medications. Although knowledge about mechanisms of action of intrathecal drugs are every day more clear many doubt remain respect the correct location of intrathecal catheter in order to achieve the best therapeutic result. We analyze the factors that can affect drug distribution within the cerebrospinal fluid. Three categories of variables were identified: drug features, cerebrospinal fluid (CSF) dynamics and patients features. First category includes physicochemical properties and pharmacological features of intrathecal administered drugs with special attention to drug lipophilicity. In the second category, the variables in CSF flow, are considered that can modify the drug distribution within the CSF with special attention to the new theories of liquoral circulation. Last category try to explain inter-individual difference in baclofen response with difference that are specific for each patients such as the anatomical area to treat, patient posture or reaction to inflammatory stimulus. We conclude that a comprehensive evaluation of the patients, including imaging techniques to study the anatomy and physiology of intrathecal environment and CSF dynamics, could become essential in the future to the purpose of optimize the clinical outcome of intrathecal therapy.

Keyword

baclofen; chronic pain; intrathecal drug delivery; opioids; spasticity

MeSH Terms

Analgesics, Opioid
Anesthetics, Local
Baclofen
Catheters
Chronic Pain
Humans
Posture
Analgesics, Opioid
Anesthetics, Local
Baclofen

Figure

• 

  Fig. 1 AP (A) and lateral (B) images of intrathecal catheter and implanted pump.

Reference

1. Ochs G, Naumann C, Dimitrijevic M, Sindou M. Intrathecal baclofen therapy for spinal origin spasticity: spinal cord injury, spinal cord disease, and multiple sclerosis. Neuromodulation. 1999; 2:108–119. PMID: 22151114.

2. Avellino AM, Loeser JD. Intrathecal baclofen for the treatment of intractable spasticity of spine or brain etiology. Neuromodulation. 2000; 3:75–81. PMID: 22151402.

3. Burns AS, Meythaler JM. Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia. Spinal Cord. 2001; 39:413–419. PMID: 11512071.

4. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989; 320:1517–1521. PMID: 2657424.

5. Plassat R, Perrouin Verbe B, Menei P, Menegalli D, Mathé JF, Richard I. Treatment of spasticity with intrathecal Baclofen administration: long-term follow-up, review of 40 patients. Spinal Cord. 2004; 42:686–693. PMID: 15303111.

6. Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012; 15:436–464. PMID: 22748024.

7. Hayek SM, Deer TR, Pope JE, Panchal SJ, Patel VB. Intrathecal therapy for cancer and non-cancer pain. Pain Physician. 2011; 14:219–248. PMID: 21587327.

8. De Andres J, Asensio-Samper JM, Fabregat-Cid G. Advances in intrathecal drug delivery. Curr Opin Anaesthesiol. 2013; [in press].

9. Kim JH, Jung JY, Cho MS. Continuous intrathecal morphine administration for cancer pain management using an intrathecal catheter connected to a subcutaneous injection port: a retrospective analysis of 22 terminal cancer patients in Korean population. Korean J Pain. 2013; 26:32–38. PMID: 23342205.

10. Erdine S, De Andrés J. Drug delivery systems. Pain Pract. 2006; 6:51–57. PMID: 17309710.

11. Loubser PG, Narayan RK, Sandin KJ, Donovan WH, Russell KD. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia. 1991; 29:48–64. PMID: 2023770.

12. Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf. 2004; 27:799–818. PMID: 15350152.

13. Francisco GE. The role of intrathecal baclofen therapy in the upper motor neuron syndrome. Eura Medicophys. 2004; 40:131–143. PMID: 16046935.

14. Deer TR, Prager J, Levy R, Burton A, Buchser E, Caraway D, et al. Polyanalgesic Consensus Conference--2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012; 15:420–435. PMID: 22494357.

15. Albright AL, Thompson K, Carlos S, Minnigh MB. Cerebrospinal fluid baclofen concentrations in patients undergoing continuous intrathecal baclofen therapy. Dev Med Child Neurol. 2007; 49:423–425. PMID: 17518926.

16. Miele VJ, Price KO, Bloomfield S, Hogg J, Bailes JE. A review of intrathecal morphine therapy related granulomas. Eur J Pain. 2006; 10:251–261. PMID: 15964775.

17. Bernards CM. Recent insights into the pharmacokinetics of spinal opioids and the relevance to opioid selection. Curr Opin Anaesthesiol. 2004; 17:441–447. PMID: 17023903.

18. Flack SH, Anderson CM, Bernards C. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg. 2011; 112:460–464. PMID: 21212256.

19. Rhee SM, Choi EJ, Lee PB, Nahm FS. Catheter obstruction of intrathecal drug administration system -a case report-. Korean J Pain. 2012; 25:47–51. PMID: 22259717.

20. Hassenbusch S, Burchiel K, Coffey RJ, Cousins MJ, Deer T, Hahn MB, et al. Management of intrathecal catheter-tip inflammatory masses: a consensus statement. Pain Med. 2002; 3:313–323. PMID: 15099236.

21. Deer TR, Levy R, Prager J, Buchser E, Burton A, Caraway D, et al. Polyanalgesic Consensus Conference--2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation. 2012; 15:467–482. PMID: 22849581.

22. Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979; 50:149–151. PMID: 373503.

23. Deer TR, Raso LJ, Garten TG. Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication. Pain Med. 2007; 8:259–262. PMID: 17371413.

24. Yaksh TL, Hassenbusch S, Burchiel K, Hildebrand KR, Page LM, Coffey RJ. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med. 2002; 3:300–312. PMID: 15099235.

25. De Andrés J, Tatay Vivò J, Palmisani S, Villanueva Pérez VL, Mínguez A. Intrathecal granuloma formation in a patient receiving long-term spinal infusion of tramadol. Pain Med. 2010; 11:1059–1062. PMID: 20642731.

26. Peng P, Massicotte EM. Spinal cord compression from intrathecal catheter-tip inflammatory mass: case report and a review of etiology. Reg Anesth Pain Med. 2004; 29:237–242. PMID: 15138910.

27. Allen JW, Horais KA, Tozier NA, Yaksh TL. Opiate pharmacology of intrathecal granulomas. Anesthesiology. 2006; 105:590–598. PMID: 16931994.

28. De Andrés J, Palmisani S, Villanueva Pérez VL, Asensio J, López-Alarcón MD. Can an intrathecal, catheter-tip-associated inflammatory mass reoccur? Clin J Pain. 2010; 26:631–634. PMID: 20639731.

29. Narouze SN, Casanova J, Souzdalnitski D. Patients with a history of spine surgery or spinal injury may have a higher chance of intrathecal catheter granuloma formation. Pain Pract. 2013; [in press].

30. Michael A, Buffen E, Rauck R, Anderson W, McGirt M, Mendenhall HV. An in vivo canine study to assess granulomatous responses in the MedStream Programmable Infusion System (TM) and the SynchroMed II Infusion System(R). Pain Med. 2012; 13:175–184. PMID: 22239738.

31. Cusato M, Allegri M, Niebel T, Ingelmo P, Broglia M, Braschi A, et al. Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate. Eur J Clin Pharmacol. 2011; 67:399–406. PMID: 21079936.

32. Reina MA, Franco CD, López A, Dé Andrés JA, van Zundert A. Clinical implications of epidural fat in the spinal canal. A scanning electron microscopic study. Acta Anaesthesiol Belg. 2009; 60:7–17. PMID: 19459550.

33. Ummenhofer WC, Arends RH, Shen DD, Bernards CM. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology. 2000; 92:739–753. PMID: 10719953.

34. Rosow CE, Dershwitz M. Pharmacology of opioid analgesics. In : Longnecker DE, Brown DL, Newman MF, Zapol WM, editors. Anesthesiology. New York (NY): McGraw-Hill;2008. p. 869–896.

35. Eisenach JC, Hood DD, Curry R, Shafer SL. Cephalad movement of morphine and fentanyl in humans after intrathecal injection. Anesthesiology. 2003; 99:166–173. PMID: 12826857.

36. Gogia V, Chaudhary P, Ahmed A, Khurana D, Mishra S, Bhatnagar S. Intrathecal morphine pump for neuropathic cancer pain: a case report. Am J Hosp Palliat Care. 2012; 29:409–411. PMID: 21868426.

37. Goodchild CS, Nadeson R, Cohen E. Supraspinal and spinal cord opioid receptors are responsible for antinociception following intrathecal morphine injections. Eur J Anaesthesiol. 2004; 21:179–185. PMID: 15055889.

38. Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, et al. Polyanalgesic Consensus Conference--2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation. 2012; 15:483–495. PMID: 22494332.

39. Georges P, Lavand'homme P. Intrathecal hydromorphone instead of the old intrathecal morphine: the best is the enemy of the good? Eur J Anaesthesiol. 2012; 29:3–4. PMID: 22127266.

40. Waara-Wolleat KL, Hildebrand KR, Stewart GR. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. Pain Med. 2006; 7:251–259. PMID: 16712626.

41. Heavner JE. Pharmacology of local anesthetics. In : Longnecker DE, Brown DL, Newman MF, Zapol WM, editors. Anesthesiology. New York (NY): McGraw-Hill;2008. p. 954–973.

42. Kumru H, Stetkarova I, Schindler C, Vidal J, Kofler M. Neurophysiological evidence for muscle tone reduction by intrathecal baclofen at the brainstem level. Clin Neurophysiol. 2011; 122:1229–1237. PMID: 20889372.

43. Natale M, Mirone G, Rotondo M, Moraci A. Intrathecal baclofen therapy for severe spasticity: analysis on a series of 112 consecutive patients and future prospectives. Clin Neurol Neurosurg. 2012; 114:321–325. PMID: 22104692.

44. Uchiyama T, Nakanishi K, Fukawa N, Yoshioka H, Murakami S, Nakano N, et al. Neuromodulation using intrathecal baclofen therapy for spasticity and dystonia. Neurol Med Chir (Tokyo). 2012; 52:463–469. PMID: 22850493.

45. Bahl A, Tripathi C, McMullan J, Goddard J. Novel use of intrathecal baclofen drug delivery system for periodic focal dystonia in a teenager. Neuromodulation. 2013; 16:273–275. PMID: 23009035.

46. Turner M, Nguyen HS, Cohen-Gadol AA. Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations. J Neurosurg Pediatr. 2012; 10:315–319. PMID: 22861196.

47. Chiodo AE, Saval A. Intrathecal baclofen for the treatment of spinal myoclonus: a case series. J Spinal Cord Med. 2012; 35:64–67. PMID: 22330193.

48. Hoarau X, Richer E, Dehail P, Cuny E. A 10-year follow-up study of patients with severe traumatic brain injury and dysautonomia treated with intrathecal baclofen therapy. Brain Inj. 2012; 26:927–940. PMID: 22668125.

49. van der Plas AA, van Rijn MA, Marinus J, Putter H, van Hilten JJ. Efficacy of intrathecal baclofen on different pain qualities in complex regional pain syndrome. Anesth Analg. 2013; 116:211–215. PMID: 23223108.

50. Schmidtko A, Lötsch J, Freynhagen R, Geisslinger G. Ziconotide for treatment of severe chronic pain. Lancet. 2010; 375:1569–1577. PMID: 20413151.

51. Alicino I, Giglio M, Manca F, Bruno F, Puntillo F. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain. 2012; 153:245–249. PMID: 22082570.

52. Dupoiron D, Bore F, Lefebvre-Kuntz D, Brenet O, Debourmont S, Dixmerias F, et al. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician. 2012; 15:395–403. PMID: 22996851.

53. Lawson EF, Wallace MS. Advances in intrathecal drug delivery. Curr Opin Anaesthesiol. 2012; 25:572–576. PMID: 22825049.

54. Wallace M, Yaksh TL. Characteristics of distribution of morphine and metabolites in cerebrospinal fluid and plasma with chronic intrathecal morphine infusion in humans. Anesth Analg. 2012; 115:797–804. PMID: 22822192.

55. Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006; 105:169–178. PMID: 16810009.

56. Loubser PG, Narayan RK. Effect of subarachnoid catheter position on the efficacy of intrathecal baclofen for spinal spasticity. Anesthesiology. 1993; 79:611–614. PMID: 8363090.

57. Flack SH, Bernards CM. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs. Anesthesiology. 2010; 112:165–173. PMID: 19996952.

58. Henry-Feugeas MC, Idy-Peretti I, Baledent O, Poncelet-Didon A, Zannoli G, Bittoun J, et al. Origin of subarachnoid cerebrospinal fluid pulsations: a phase-contrast MR analysis. Magn Reson Imaging. 2000; 18:387–395. PMID: 10788715.

59. Hsu Y, Hettiarachchi HD, Zhu DC, Linninger AA. The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability. Anesth Analg. 2012; 115:386–394. PMID: 22523420.

60. Martin BA, Reymond P, Novy J, Balédent O, Stergiopulos N. A coupled hydrodynamic model of the cardiovascular and cerebrospinal fluid system. Am J Physiol Heart Circ Physiol. 2012; 302:H1492–H1509. PMID: 22268106.

61. Prats-Galino A, Reina MA, Puigdellívol-Sánchez A, Juanes Méndez JA, De Andrés JA, Collier CB. Cerebrospinal fluid volume and nerve root vulnerability during lumbar puncture or spinal anaesthesia at different vertebral levels. Anaesth Intensive Care. 2012; 40:643–647. PMID: 22813492.

62. Sivakumar G, Yap Y, Tsegaye M, Vloeberghs M. Intrathecal baclofen therapy for spasticity of cerebral origin--does the position of the intrathecal catheter matter? Childs Nerv Syst. 2010; 26:1097–1102. PMID: 20306056.

63. McCall TD, MacDonald JD. Cervical catheter tip placement for intrathecal baclofen administration. Neurosurgery. 2006; 59:634–640. PMID: 16955045.

64. Deer TR, Raso LJ, Coffey RJ, Allen JW. Intrathecal baclofen and catheter tip inflammatory mass lesions (granulomas): a reevaluation of case reports and imaging findings in light of experimental, clinicopathological, and radiological evidence. Pain Med. 2008; 9:391–395. PMID: 18489628.